Publications by authors named "Cheryl A Dixon"
Article Synopsis
- On March 22, 2023, the FDA approved rezafungin (Rezzayo) for treating candidemia and invasive candidiasis in adults lacking alternative treatments.
- Rezafungin is an echinocandin that allows for weekly dosing, potentially reducing the need for central venous catheters by enabling outpatient treatment.
- The approval was based on a phase 3 study showing rezafungin's effectiveness compared to other echinocandins, with identified safety concerns from animal studies being consistent with the safety profiles of existing approved drugs.
